Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults

View ORCID ProfileHelen Ward, View ORCID ProfileChristina Atchison, Matthew Whitaker, View ORCID ProfileKylie EC Ainslie, Joshua Elliott, Lucy Okell, Rozlyn Redd, View ORCID ProfileDeborah Ashby, View ORCID ProfileChristl A Donnelly, View ORCID ProfileWendy Barclay, View ORCID ProfileAra Darzi, Graham Cooke, View ORCID ProfileSteven Riley, Paul Elliott
doi: https://doi.org/10.1101/2020.08.12.20173690
Helen Ward
1School of Public Health, Imperial College London; Imperial College Healthcare NHS Trust; National Institute for Health Research Imperial Biomedical Research Centre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Helen Ward
Christina Atchison
2School of Public Health, Imperial College London; Imperial College Healthcare NHS Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christina Atchison
Matthew Whitaker
3School of Public Health, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kylie EC Ainslie
4School of Public Health, Imperial College London; MRC Centre for Global Infectious Disease Analysis Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kylie EC Ainslie
Joshua Elliott
5School of Public Health, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucy Okell
6School of Public Health, Imperial College London; MRC Centre for Global Infectious Disease Analysis Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rozlyn Redd
7School of Public Health, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah Ashby
8School of Public Health, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Deborah Ashby
Christl A Donnelly
9School of Public Health, Imperial College London; MRC Centre for Global Infectious Disease Analysis, Imperial College London; Department of Statistics, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christl A Donnelly
Wendy Barclay
10Department of Infectious Disease, Imperial College London; Imperial College Healthcare NHS Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wendy Barclay
Ara Darzi
11Institute of Global Health Innovation, Imperial College London; Imperial College Healthcare NHS Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ara Darzi
Graham Cooke
12Department of Infectious Disease, Imperial College London; Imperial College Healthcare NHS Trust; National Institute for Health Research Imperial Biomedical Research Centre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Riley
13School of Public Health, Imperial College London; MRC Centre for Global Infectious Disease Analysis, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven Riley
Paul Elliott
14School of Public Health, Imperial College London; Imperial College Healthcare NHS Trust; National Institute for Health Research Imperial Biomedical Research Centre; MRC Centre for Environment and Health, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: p.elliott@imperial.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background England, UK has experienced a large outbreak of SARS-CoV-2 infection. As in USA and elsewhere, disadvantaged communities have been disproportionately affected.

Methods National REal-time Assessment of Community Transmission-2 (REACT-2) prevalence study using a self-administered lateral flow immunoassay (LFIA) test for IgG among a random population sample of 100,000 adults over 18 years in England, 20 June to 13 July 2020.

Results Data were available for 109,076 participants, yielding 5,544 IgG positive results; adjusted (for test performance) and re-weighted (for sampling) prevalence was 6.0% (95% Cl: 5.8, 6.1). Highest prevalence was in London (13.0% [12.3, 13.6]), among people of Black or Asian (mainly South Asian) ethnicity (17.3% [15.8, 19.1] and 11.9% [11.0, 12.8] respectively) and those aged 18-24 years (7.9% [7.3, 8.5]). Adjusted odds ratio for care home workers with client-facing roles was 3.1 (2.5, 3.8) compared with non-essential workers. One third (32.2%, [31.0-33.4]) of antibody positive individuals reported no symptoms. Among symptomatic cases, most (78.8%) reported symptoms during the peak of the epidemic in England in March (31.3%) and April (47.5%) 2020. We estimate that 3.36 million (3.21, 3.51) people have been infected with SARS-CoV-2 in England to end June 2020, with an overall infection fatality ratio (IFR) of 0.90% (0.86, 0.94); age-specific IFR was similar among people of different ethnicities.

Conclusion The SARS-CoV-2 pandemic in England disproportionately affected ethnic minority groups and health and care home workers. The higher risk of infection in minority ethnic groups may explain their increased risk of hospitalisation and mortality from COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded by the Department of Health and Social Care in England. HW is a NIHR Senior Investigator and acknowledges support from NIHR Biomedical Research Centre of Imperial College NHS Trust, NIHR School of Public Health Research, NIHR Applied Research Collaborative North West London, Wellcome Trust (UNS32973). GC is supported by an NIHR Professorship. WSB is the Action Medical Research Professor, AD is an NIHR senior investigator and DA is an Emeritus NIHR Senior Investigator. SR acknowledges support from MRC Centre for Global Infectious Disease Analysis, National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU), Wellcome Trust (200861/Z/16/Z, 200187/Z/15/Z), and Centres for Disease Control and Prevention (US, U01CK0005-01-02) PE is Director of the MRC Centre for Environment and Health (MR/L01341X/1, MR/S019669/1). PE acknowledges support from the NIHR Imperial Biomedical Research Centre and the NIHR HPRUs in Environmental Exposures and Health and Chemical and Radiation Threats and Hazards, the British Heart Foundation Centre for Research Excellence at Imperial College London (RE/18/4/34215) and the UK Dementia Research Institute at Imperial (MC_PC_17114).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Supplemental files were updated to include Table S2(b): Estimated infection fatality ratios and total infected population by ethnicity, age and sex

Data Availability

The original datasets generated or analysed, or both, during this study are not publicly available because of governance restrictions and the identifiable nature of the data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 21, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults
Helen Ward, Christina Atchison, Matthew Whitaker, Kylie EC Ainslie, Joshua Elliott, Lucy Okell, Rozlyn Redd, Deborah Ashby, Christl A Donnelly, Wendy Barclay, Ara Darzi, Graham Cooke, Steven Riley, Paul Elliott
medRxiv 2020.08.12.20173690; doi: https://doi.org/10.1101/2020.08.12.20173690
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults
Helen Ward, Christina Atchison, Matthew Whitaker, Kylie EC Ainslie, Joshua Elliott, Lucy Okell, Rozlyn Redd, Deborah Ashby, Christl A Donnelly, Wendy Barclay, Ara Darzi, Graham Cooke, Steven Riley, Paul Elliott
medRxiv 2020.08.12.20173690; doi: https://doi.org/10.1101/2020.08.12.20173690

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (945)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8976)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1940)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1323)
  • Health Policy (657)
  • Health Systems and Quality Improvement (518)
  • Hematology (212)
  • HIV/AIDS (417)
  • Infectious Diseases (except HIV/AIDS) (10780)
  • Intensive Care and Critical Care Medicine (573)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (221)
  • Neurology (1820)
  • Nursing (109)
  • Nutrition (271)
  • Obstetrics and Gynecology (352)
  • Occupational and Environmental Health (470)
  • Oncology (995)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1894)
  • Public and Global Health (4117)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (364)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)